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While spleen and other secondary tissue sites contribute to hematopoiesis, the nature of cells produced and the environment under
which this happens are not fully defined. Evidence is reviewed here for hematopoiesis occurring in the spleen microenvironment
leading to the production of tissue-specific antigen presenting cells. The novel dendritic-like cell identified in spleen is
phenotypically and functionally distinct from other described antigen presenting cells. In order to identify these cells as distinct,
it has been necessary to show that their lineage origin and progenitors differ from that of other known dendritic and myeloid
cell types. The spleen therefore represents a distinct microenvironment for hematopoiesis of a novel myeloid cell arising from
self-renewing hematopoietic stem cells (HSC) or progenitors endogenous to spleen.
1. Hematopoiesis in the Mouse Model
Hematopoietic stem cells arise in the embryo from an
hemangioblast present in yolk sac and aorta-gonad-
mesonephros. They then migrate into fetal liver and spleen,
entering bone marrow in the late embryonic period [1].
Numbers of HSC increase in bone marrow and spleen in the
neonatal period and are then maintained in those organs for
life [2, 3]. HSC migration into bone marrow at birth then
determines bone as the dominant site for hematopoiesis in
adults. HSC have also been identified in extramedullary sites
in the steady state and small numbers also mobilize through
blood and lymph into sites like liver, spleen, brain, lung and
intestine [4, 5]. Infection, inflammation, or drug treatment
can lead to expansion in the number of hematopoietic
stem/progenitor cells (HSPC) circulating in blood and
entering tissues like spleen and liver [6, 7]. Despite the small
numbers of HSPC present in extramedullary tissues in the
steady state, this fact should not discount their importance
or potential contribution to the development of the immune
system and immune responsiveness. Findings from this lab
indicate that spleen in the steady state contains HSC [2] and
that these undergo myelopoiesis within spleen giving rise to
a novel type of dendritic-like antigen presenting cell [8].
2. The Hematopoietic Stem Cell
Bone marrow is a very rich source of HSC and for decades
bone marrow transplants have provided HSC for regener-
ation of the hematopoietic system in humans. HSC have
distinguishing properties of self-renewal, asymmetric cell
division, and ability to clonally regenerate all hematopoietic
cell types. Methodology for sorting HSC from bone marrow
using specific antibodies and flow cytometry [9] has become
a standard technique in many labs. HSC are heteroge-
neous, comprising cells with both long-term and short-term
reconstitution capacity [10, 11]. Long-term reconstituting
HSC are commonly isolated from murine bone marrow as
lineage (Lin)−Sca-1+c-kit+Flt3− cells [11] and can be further
purified as the CD150+CD48− subset of Lin−Sca1+ckit+
bone marrow [12, 13]. Epigenetic imprinting of HSC
also contributes to differences in hematopoietic potential
[14]. Given the level of heterogeneity amongst HSC, it is
important to consider them in relation to their tissue niche
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of origin, their distinct hematopoietic potential, and to
use this knowledge to inform HSC transplantation in the
clinic. Most studies have concentrated on the more prevalent
HSC in bone marrow with less attention given to HSC in
extramedullary sites like spleen. While HSC from tissue sites
like bone marrow, cord blood and spleen can reconstitute
all cell lineages, there has been no comprehensive study of
their relative capacity to produce a range of hematopoietic
cell subsets. The hematopoietic support capacity of different
tissue niches is also a factor not yet investigated in terms of
hematopoietic output. Recent evidence that spleen supports
the development of distinct dendritic-like antigen presenting
cells suggests that spleen may contribute in a distinct, tissue-
specific manner to hematopoiesis.
3. The Spleen in Hematopoiesis
HSC represent a rare subset in adult mouse spleen. They are
however readily detectable by their long-term reconstitution
ability upon adoptive transfer into irradiated host mice
[2, 3] (Figure 1). The weaker contribution of splenic HSC
compared with bone-marrow-derived HSC to hematopoiesis
in the normal animal has been reported [15]. It has long
been assumed that spleen fills the role of an emergency
or backup site for cell development at times of stress or
disease. Indeed, the importance of bone marrow over spleen
in hematopoiesis is evident since neonatally splenectomised
mice can maintain normal bone marrow hematopoiesis [16].
However, a distinct role for spleen in hematopoiesis has not
yet been fully investigated in terms of development of indi-
vidual cell subsets. During embryogenesis, spleen harbours
myeloid cells seeding from fetal liver and does not appear to
become colonized with HSC until around the time of birth
[3]. Evidence that splenectomy in newborn mice results in
a dramatic increase in colony forming cells in liver suggests
that HSC entering spleen at this time may seed directly into
spleen from fetal liver rather than from bone marrow [3].
Spleen could therefore become colonized by HSC during
development resulting in an endogenous HSC population.
Such a model would not however preclude later or additional
entry of bone-marrow-derived HSC at times of stress or
inflammation, or following stem cell transplantation.
Spleen is also a central organ for development of den-
dritic cells (DC) that initiate immune responses by taking
up and presenting antigen to lymphocytes. Murine spleen
contains multiple subsets of DC including the CD8α−
and CD8α+ conventional(c)DC, plasmacytoid(p)DC [17],
and regulatory DC which are not well characterised [18].
Monocyte-derived DC are also found in spleen but only
under conditions of inflammation [19]. Very few markers
distinguish these subsets and they are best distinguished by
their distinct function in immunity. Both cDC subsets are
powerful T-cell activators, although the CD8α− cDC are
located in the marginal zone of spleen where antigen enters
from blood, while the CD8α+ cDC are located in the T-
cell areas where they are poised for T-cell stimulation. The
CD8α− cDC preferentially activate a T-helper(h)2 response
with T-cell production of interleukin(IL)-4 and IL-10, while
CD8α+ cDC preferentially induce a Th1 response marked by
interferon (IFN)-γ production [20, 21]. While both subsets
of cDC can activate CD4+ and CD8+ T cells, the CD8α+
cDC subset has been shown to be superior at antigen cross-
presentation [22]. Plasmacytoid DC are distinct in that they
reside mainly in blood in a precursor form, often referred to
as p-preDC. They are distinct by their capacity to produce
high levels of IFN-α in response to viruses [23]. Regulatory
DCs represent a poorly defined class of DCs which are
inhibitory rather than stimulatory for T cells, producing
factors like IL-10 and nitric oxide [18, 24]. In contrast to
cDC and pDC, mo-DCs are not detectable in spleen in
the resting state. They develop from blood monocytes in
response to inflammatory factors. Tumour necrosis factor
α/inducible nitric oxide synthase producing (Tip) DC derive
from monocytes and enter tissues where they function as
strong T-cell activators [25].
An essential element of DC biology is the definition
of progenitors and precursors since this underpins the
formation of lineages of cells with distinct function. Ini-
tially cDC and pDC progenitors were defined as a Flt3+
subset amongst common myeloid and lymphoid progenitors
(CMP/CLP) in bone marrow [26]. Recent evidence now
points to a monocyte/dendritic progenitor (MDP) in bone
marrow which gives rise to all monocyte/macrophage and
dendritic type cells [27, 28], as well as a more committed
common dendritic progenitor (CDP) for cDC and pDC
in bone marrow [29, 30]. While CDP and MDP are not
present in spleen or blood [31], spleen does harbour more
differentiated cDC precursors which have a high turnover
and are replaced by blood-borne precursors migrating from
bone marrow [32]. Studies with parabiotic mice that share a
circulatory system, suggest that some splenic DC might arise
from endogenous progenitors [33], although others have
questioned that result [34]. The presence of an endogenous
hematopoietic progenitor in spleen that differentiates to give
a novel and distinct dendritic-like cell is now indicated by the
findings described below.
4. A Novel Antigen Presenting
Cell Subset in Spleen
Distinct myeloid dendritic-like cells have been discovered as
a subset in murine spleen [35] on the basis of similarity
with dendritic-like cells identified previously which develop
in splenic longterm cultures (LTC) [36–38]. LTC-derived DC
and the in vivo subset of “L-DC”, have a characteristic imma-
ture phenotype as CD11cloCD11bhiMHC-II−CD8α− cells,
distinguishing them from cDC, pDC, and monocytes [35]
(Figure 2). They are large, endocytic cells specialized in cross-
presentation of antigen to CD8+ T cells, a function usually
attributed to CD8α+ cDC [39]. LTC-DC are also distinct by
their very weak ability to activate CD4+ T cells and their
MHC-II− phenotype, properties which distinguish them
from all of the common subsets of CD8α+ cDC, CD8α− cDC,
and pDC [35, 37, 40]. Since LTC-DC can be derived from
GM-CSF−/− mice [41], they do not resemble monocyte-
derived DC that develop in response to inflammatory factors
like GM-CSF and TNF-α [19].
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Figure 1: Hematopoietic reconstitution assay for detecting the presence of HSC. The hematopoietic system of lethally irradiated host mice
can be fully reconstituted with lymphoid, myeloid, erythroid, and dendritic cells following adoptive transfer of bone marrow cells as a source
of HSC. In order to assess the presence of HSC or other hematopoietic progenitors in a test population of cells, CD45-allotype distinct
cells are adoptively transferred with assessment of the hematopoietic reconstitution capacity of this specific population by flow cytometry.
In most cases, test animals are also given an inoculum of host type bone marrow to ensure survival. HSC with long-term reconstitution
potential produce progeny out to 25 weeks, while HSC with short-term potential are assessed after 8 weeks.
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Figure 2: Classification of DC and myeloid subsets in spleen. Subsets in spleen can be identified flow cytometrically in terms of their
phenotype following staining with specific antibody to cell surface markers. The different subsets can be identified based on variant
expression of CD11c, CD11b, CD8α and MHC-II. The phenotype of L-DC is shown by comparison with pDC, cDC and a broad monocyte
population. The different subsets can also be located in distinct positions on a bivariate CD11c versus CD11b scatter plot.
An isolation procedure was optimised to reveal the
in vivo equivalent cell type to LTC-DC [35]. This proce-
dure distinguished CD8α+ cDC, CD8α− cDC, pDC and
monocytes on the basis of CD11b, CD11c, MHC-II and
CD8α expression, from a population of cells of large size
(FSChi) resembling LTC-DC by their CD11cloCD11bhiMHC-
II−CD8α− phenotype and their high endocytic capacity for
soluble antigen (Figure 3). These cells have been tentatively
named “L-DC,” since they resemble a DC more than a
myeloid cell. L-DC are phenotypically and functionally
distinct from monocytes/macrophages, cDC and pDC. They
are distinct as CD11c+ cells that are highly cross-presenting,
a property which distinguishes them from common subsets
of macrophages and monocytes [40]. Recent evidence for
uniform expression of F4/80 and CD11c, but not Ly6G,
also distinguishes L-DC from neutrophils [42]. The immune
potential of this in vivo subset is under continued investiga-
tion in terms of both T-cell and B-cell immunity. Already
we know that L-DC share similar antigen cross-presenting
function for CD8+ T-cell activation with LTC-DC [35]. Like
LTC-DC, they are also unable to activate CD4+ T cells,
consistent with the absence of MHC-II expression [37, 40].
Despite their distinct functional potential, the lineage origin
of L-DC relative to other known splenic myeloid and DC
subsets, is still unknown.
The distinctiveness of L-DC from monocytes, cDC
subsets and granulocytes has been confirmed by tran-
scriptome analysis of subsets sorted as shown in Figure 3.
Principal Components Analysis of the data indicated a
broad separation of overall gene expression between L-
DC and other subsets, with CD8α+ and CD8α− cDC the
most closely related subsets (Figure 4). L-DC specifically
express high levels of Treml4, a gene recently identified as
expressed by CD8α+ but not CD8α− cDC and by splenic
red pulp and metallophilic macrophages [43]. This gene
encodes a receptor that binds late apoptotic and necrotic
cells, consistent with cross-presenting capacity related to the
uptake of dead and dying cells from blood. The relationship
between L-DC and other DC and macrophage cell types is
currently under investigation.
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Figure 3: Isolation of L-DC (LIVE-DC) in spleen amongst other DC subsets. Spleens were depleted of T and B cells using antibody-coated
magnetic beads and then stained with antibodies specific for CD11c, CD11b, CD8α and MHC-II ahead of flow cytometric analysis. DC
subsets were identified based on multiple parameters of forward scatter (FSC), side scatter (SSC), marker expression and endocytosis after
intravenous administration of FITC-OVA (0.6 mg/mouse) 24 hours previously.
5. Hematopoiesis Leading to L-DC
Production In Vitro
Coculture assays are now used instead of LTC to produce
L-DC in vitro. These involve overlay of Lin− BM or T/B-
cell-depleted spleen cell suspensions over competent splenic
stroma [40]. The splenic stromal line STX3 and its 5G3 clone
originated from a long-term splenic culture that had lost
hematopoietic progenitors over time and passage [40]. The
5G3 clone of STX3 has been characterized as an immature
endothelial-like cell [44, 45], unique in its phenotype and
function as a supporter of in vitro hematopoiesis of L-DC.
There also appears to be no equivalent stromal cell line
reported in the literature. Cells produced in cocultures over
35 days both phenotypically and functionally resemble LTC-
DC as well as the in vivo L-DC subset [8, 40]. Cocultures
can therefore be used to identify L-DC progenitors amongst
sorted cell subsets by their capacity to seed stroma for
continued L-DC production in vitro. Indeed, the continuous
nature of LTC which produce dendritic-like cells over several
years [36], as well as the ability of STX3 or 5G3 stroma to
support in vitro hematopoiesis of L-DC for up to a year
[46], suggests that the L-DC progenitor may represent a self-
renewing HSPC.
The development of L-DC in LTC depends on the
maintenance of a population of small progenitors [38, 47].
In fact, the requirement for differentiation of progenitors was
demonstrated by sorting the small progenitor population
in LTC and showing that these cells produced L-DC upon
transfer to stromal cocultures [38]. L-DC were however
shown to undergo several rounds of proliferation in bromo-
deoxyuridine labeling experiments [47]. The production of
dendritic-like cells by differentiation from HSPC maintained
within LTC as opposed to proliferation of L-DC was also
confirmed by gene profiling of subtracted libraries prepared
between the purified small and large cells maintained in
LTC [48]. These studies showed that small cells resemble
HSPC, while large cells reflect myeloid dendritic cells. More
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Figure 4: Relatedness of transcriptome between L-DC (LIVE-DC) and other spleen myeloid subsets. Myeloid and DC subsets were isolated
from spleen by antibody staining and cell sorting using flow cytometry as demonstrated in Figure 3. RNA was prepared from DC subsets
described in Figure 2, and from granulocytes (GRAN) as Gr-1+CD11b+CD11c− cells and monocytes (MONO) as CD11b+CD11c−MHC-II−
cells. RNA was used to probe Affymetrix Gene 1.0ST microarrays. Data show Principal Components Analysis (1&2) reflecting degree of
relatedness in overall gene expression between subsets.
recent studies have involved phenotypic characterization of
progenitors. Over many experiments, progenitor activity was
found to be enriched within the subset of Lin−ckit+CD34−/+
“small” cells in LTC, a phenotype reflective of described
subsets of HSC differing in terms of long-term or short-
term reconstituting capacity [11]. Highly purified, sorted
HSC from bone marrow have now been shown to seed
STX3 cocultures to produce L-DC, but only when contact
is maintained with stroma [46]. Cells produced were found
to phenotypically resemble L-DC. Overall, these results
align the L-DC progenitor with the HSC subset in bone
marrow. This finding is particularly important in terms
of the relationship between the L-DC progenitor and the
progenitors of cDC and pDC which have been identified
as MDP, CDP and myeloid progenitors (MP), which are
present in bone marrow but not spleen [31]. One hypothesis
is that splenic niches are distinct from bone marrow niches
and can support the direct differentiation of HSC to give
L-DC in the apparent absence of committed myeloid or
dendritic progenitors like the MDP, CDP and MP. The
relationship between these progenitors and a putative L-
DC progenitor in spleen is not known and warrants further
investigation.
6. Identification of L-DC
Progenitors in Spleen
To delineate the L-DC progenitor in mouse spleen, Lin−
splenocytes were assessed for expression of ckit and other
markers of early hematopoietic progenitors followed by
sorting of subsets of interest. Sorted subsets were each
assessed for their hematopoietic potential in cocultures of
competent stroma. They were also tested in vivo for capacity
to reconstitute lethally irradiated CD45-allotype distinct host
mice also given syngeneic bone marrow to aid recovery [8]
(Figure 1). The Lin−ckitlo spleen subset produced exclusively
L-DC in cocultures, and the Lin−ckithi subset produced
predominantly L-DC with a few cDC-like cells that were not
maintained over time. However, only Lin−ckithi splenocytes,
and not the Lin−ckitlo or Lin−ckit− subsets, showed multi-
lineage reconstitution in vivo consistent with the presence
of HSC [8]. The Lin−ckithi population of spleen therefore
contains long-term reconstituting HSC as well as L-DC
progenitors, while the Lin−ckitlo fraction contains only L-
DC progenitors. One explanation is that there is a common
progenitor within each of these two populations. Another is
that there are distinct progenitors within the two subsets and
that the stroma supports differentiation of ckithi progenitors
to give ckitlo progenitors. The relationship between the L-
DC progenitor and the HSC subset in spleen is unclear at
present. These findings are also consistent with evidence
that bone-marrow-derived HSC can seed stroma for L-DC
production and that the L-DC progenitor maintained in
LTC is represented by a Lin−ckit+CD34+/− subset. Splenic
stroma therefore appears to impose specific differentiative
capacity on HSC, irrespective of their origin from spleen
or bone marrow. In terms of the characterization of L-
DC progenitors endogenous to spleen, a first goal will be
to fractionate subsets of splenic Lin−ckit+ cells further and
to identify the minimum subset that produces L-DC in
cocultures.
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7. Does Hematopoiesis in Spleen Involve
an Endogenous Progenitor?
Many studies now indicate a specific role for splenic niches
in the development of the novel antigen presenting cell
subset, namely L-DC. While the in vitro evidence is direct
and compelling, it is a harder task to delineate L-DC
production in vivo as dependent on hematopoiesis occurring
in spleen and arising from an HSPC endogenous to spleen.
In experiments involving adoptive transfer of stem cells into
irradiated mice (Figure 1), the issue of where in the animal
hematopoiesis occurs is not clear. Transferred stem cells can
migrate to and localize in multiple niches in spleen and bone
marrow. In these sites, they can undergo hematopoiesis and
then migrate into other lymphoid areas. Another more direct
method to delineate hematopoiesis specific to splenic HSC
involves ectopic grafting of allotype-distinct spleen or spleen
fragments under the kidney capsule of splenectomized mice
and monitoring the output of donor graft-derived mature
cells on the basis of allotype markers. We recently published
successful engraftment of neonatal spleen fragments under
the kidney capsule of splenectomized mice [49]. Most
grafts retained donor-type HSC and showed development
of some donor-type myeloid cells at 2 weeks. However,
recruitment of host HSC, lymphocytes and myeloid cells into
grafts was also evident [49]. The spleen microenvironment
therefore appears to support myelopoiesis and possibly L-
DC development. The development of individual subsets of
myeloid cells is yet to be analysed more completely using this
model.
Indirect evidence that spleen supports hematopoiesis
and the specific differentiation of L-DC also comes from
chimera studies. These studies compared the relative ability
of splenic versus bone marrow HSC to generate the different
myeloid and DC subsets including L-DC [2]. In several
studies, analysis of the relative numbers of donor : host
progeny cells representing each of the common DC and
myeloid subsets produced in chimeras identified a distinct
developmental bias towards donor L-DC over other myeloid
and DC subsets [2]. The only explanation for this finding is
that splenic niches preferentially support the development
of L-DC from HSC. Another consideration is whether the
microenvironment in which HSC develop conditions their
hematopoietic capacity. In terms of stem cell transplantation,
it will be important to determine whether HSC arising in
BM, spleen, or fetal liver can adopt distinct differentiative
capacity after residence in splenic niches.
8. Conclusion
A history of published work now supports the hypothesis
that the splenic L-DC subset described here represents a
functionally distinct tissue-specific antigen presenting cell
type that develops within spleen from endogenous HSPC.
Its development is entirely dependent on endothelial niches
within spleen although bone-marrow-derived HSC can also
differentiate within this niche to produce L-DC. The hypoth-
esis that spleen contains an endogenous HSC laid down
during embryogenesis would be consistent with evidence for
tissue-specific hematopoiesis of L-DC.
The identification of a novel antigen presenting cell
subset with unique immune function is of significant
immunological interest. It is therefore important to define
the hematopoietic pathways in spleen that lead to devel-
opment of these dendritic-like cells, especially since these
cells do not appear to have a lineage origin in common
with other described cDC and myeloid subsets. Indeed, there
are now a number of examples in the literature of tissue-
specific antigen presenting cells developing from endogenous
progenitors maintained in distinct tissue sites. For example,
Langerhans cells in skin arise from epidermal progenitors
that colonize embryonic skin [50], and microglia represent
antigen presenting cells in brain which develop from self-
renewing progenitors induced to proliferate after inflamma-
tion [51]. These examples support a model for compart-
mentalization of the immune response by the production of
tissue-specific antigen presenting cells, and specialization of
immunity in tissues colonized by particular pathogens. A full
understanding of hematopoiesis occurring in extramedullary
sites will be essential knowledge for therapeutic practice in
immunotherapy and indeed in HSC transplantation.
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